Martingale Asset Management L P Has $812,000 Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Martingale Asset Management L P decreased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 39.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,434 shares of the company’s stock after selling 1,600 shares during the period. Martingale Asset Management L P’s holdings in Medpace were worth $812,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Westwind Capital boosted its holdings in shares of Medpace by 800.1% during the 2nd quarter. Westwind Capital now owns 380,929 shares of the company’s stock worth $156,886,000 after buying an additional 338,610 shares in the last quarter. Clearbridge Investments LLC boosted its stake in Medpace by 55.1% during the second quarter. Clearbridge Investments LLC now owns 403,892 shares of the company’s stock worth $166,343,000 after acquiring an additional 143,481 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Medpace by 38.3% in the second quarter. Renaissance Technologies LLC now owns 443,588 shares of the company’s stock worth $182,692,000 after purchasing an additional 122,800 shares during the period. AQR Capital Management LLC increased its stake in Medpace by 62.3% in the second quarter. AQR Capital Management LLC now owns 310,650 shares of the company’s stock valued at $127,941,000 after purchasing an additional 119,257 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of Medpace by 1,028.5% during the second quarter. Allspring Global Investments Holdings LLC now owns 116,683 shares of the company’s stock valued at $48,056,000 after purchasing an additional 106,343 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Price Performance

MEDP opened at $342.36 on Tuesday. The firm’s fifty day moving average price is $337.43 and its two-hundred day moving average price is $370.62. The company has a market capitalization of $10.64 billion, a price-to-earnings ratio of 29.98, a P/E/G ratio of 1.88 and a beta of 1.37. Medpace Holdings, Inc. has a 1 year low of $273.14 and a 1 year high of $459.77.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.24. The business had revenue of $533.32 million for the quarter, compared to analysts’ expectations of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The firm’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same period in the previous year, the company earned $2.22 earnings per share. As a group, equities analysts anticipate that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on MEDP. Robert W. Baird boosted their target price on Medpace from $349.00 to $354.00 and gave the company a “neutral” rating in a research report on Monday, November 25th. Truist Financial decreased their price objective on Medpace from $415.00 to $397.00 and set a “hold” rating for the company in a report on Monday, October 14th. TD Cowen cut their target price on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. William Blair restated an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Finally, StockNews.com downgraded shares of Medpace from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $380.56.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.